BSR maintains formal coverage on over two dozen development-stage biotechnology companies. Having a company in our coverage universe does not necessarily mean we see them as a good investment. Our opinions on the companies appearing below range from a belief they should be overweight in a diversified biotechnology portfolio to a determination they are not suitable for investment capital. Clicking on the name of the company takes you to a list of everything we've published on the company.

Company	Ticker	First coverage
Adolor	ADLR	March 2003
Altus Pharma	ALTU	September 2006
Amicus Therapeutics	FOLD	October 2007
BioMarin Pharmaceuticals	BMRN	October 2004
CombinatoRx	CRXX	January 2007
Corcept Therapeutics	CORT	September 2004
Dendreon	DNDN	February 2001
Discovery Labs	DSCO	October 2002
Dynavax	DVAX	July 2006
Hana Biosciences	HNAB	February 2006
Indevus Pharma	IDEV	February 2002
Medarex	MEDX	December 2003
Oncolytics Biotech	ONCY	June 2005
Osmetech	AIM:OMH	February 2008
OXiGENE	OXGN	July 2007
Pipex Pharmaceuticals	PP	September 2007
Repros Therapeutics	RPRX	February 2006
Resverlogix	TSE:RVX	April 2003
SciClone Pharma	SCLN	April 2003
Seattle Genetics	SGEN	June 2002
Sonus Pharma	SNUS	May 2003
Targeted Genetics	TGEN	August 2001
YM Biosciences	YMI	November 2005
ZymoGenetics	ZGEN	November 2002

---